Shares of Illumina (ILMN) were lower Tuesday after the biotech firm cut its third-quarter sales expectations to $607 million, that's down more than 3% from the midpoint of its prior guidance. Illumina also said it expects to see a fall in sales of its sequencing instruments. Analysts with Cantor Fitzgerald wrote Tuesday that Illumina's troubles are "largely company-specific" and that Cantor Fitzgerald is still positive on industry peers such as Pacific Biosciences (PACB) .
More from Video
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Breaking down an approach to the long side of this biotech stock.
AMSC CEO discusses that and China challenges.
One of pharma's biggest CEO's talks M&A action on the exchange.